Axxam SpA is a member of the PHAGO Consortium

Milan (Italy) – January, 11th 2017 – Axxam is proud to announce its participation to the PHAGO project, an innovative research project devoted to the development of immunomodulatory therapies for Alzheimer’s disease (AD). Axxam will contribute its expertise for the development of high-throughput screening systems suitable for the discovery of modulators of the TREM2/CD33 pathway. For more information please open the Press Release from the Phago Consortium.

Open PDF document